Constituent: You talked about abuses in the medicare and medicaid system and I found interesting that the president pardoned someone that defrauded the medicaid system for $1.3 billion
Flagrantly. Wow.
Dr. Irl Hirsch, a @uwmedicine.bsky.social endocrinologist said controlling blood glucose with leptin could unlock new avenues of treatment for patients. “This is one of the most exciting discoveries of my career,” said Hirsch. #diabetes
Hear me out: What if there was a way for ALL corporations to make regular payments of some set percentage of their profits to the Treasury?
Remember, it is the biggest injustice in history to hold J6 insurrectionists accountable for indisputable illegal acts, but prosecuting this guy for a felony is just America first.
Does she actually mean "tranquilizers" though? Sometimes these things get lost in translation from the original Russian coming in through her earpiece.
My God…💔🇺🇸
LMAOOOO
www.instagram.com/reel/DK2nMmJ...
Slowly this country is being transformed into a third world nation.
The hospital
WHY DOES SHE HAVE THE GREATEST ARTISTS OF ALL-TIME & I ONLY GET KID ROCK??? WAAAAAHHH!!!!! 😩
If this person sat next to you on a bus or train and started ranting about Bruce Springsteen in this way, you would get up and move to a different seat.
In the United States, we have him the nuclear codes.
Personal Best in the human race. EQ off the charts...I don't have the confidence to say "the kids are alright", but this one is. :)
Oh, that's HER BABY!💕
Congratulations to your family! Is she jealous yet???
Banning The Grapes of Wrath. Pure Orwell.
Welcome to the DOGE Subcommittee—this is what it has become. They can gavel me all day—but I will always fight for what is right—at home and in Washington.
Ideal time to release the Trickle Down Barbie.
Kudos to Cecilia Low Wang on her team’s paper on combining a community health worker program with remote care monitoring to improve outcomes for those with type 2 #diabetes living in rural communities around Colorado.
www.sciencedirect.com/science/arti...
SUMMARY Researchers have developed a tau-targeting vaccine that could help prevent the progression of Alzheimer's disease by generating a strong immune response against abnormal tau proteins. The vaccine showed effectiveness in mice and non-human primates, prompting researchers to pursue human clinical trials. It targets a specific region of the tau protein, pT181, linked to Alzheimer's-related brain damage and cognitive decline. If successful in humans, this approach could complement or even surpass current therapies that only modestly impact disease progression by targeting amyloid beta. KEY FACTS •Tau-Targeting Vaccine: Generates antibodies against pT181, a hallmark of Alzheimer's pathology. • Strong Immune Response: Proven effective in mice and macaques, with long-lasting immunity. •The vaccine improved memory, reduced brain atrophy, and caused NO major side effects. •Clinical Trials Ahead: Researchers are preparing for Phase I human trials pending funding.
ABSTRACT INTRODUCTION Pathological accumulation of tau (pTau) contributes to various tauopathies, including Alzheimer's disease (AD), and correlates with cognitive decline. A rapid surge in tau-targeted approaches via anti-sense oligonucleotides, active/passive immunotherapies suggests that targeting p-Tau is a viable strategy against tauopathies. METHOD We describe a multi-species validation of our previously described Qß virus-like particle (VLP)-based vaccine technology targeting phosphorylated tau on threonine 181 (pT181-Qß). RESULTS Two vaccine doses of pT181-Qß, without any adjuvants, elicited robust antibody responses in two different mouse models of tauopathy (PS19 and hTau) and rhesus macaques. In mouse models, vaccination reduced AT180+ hyperphosphorylated, Sarkosyl insoluble, Gallyas silver positive tau, inflammasomes/ neuroinflammation, and improved recognition memory and motor function without inducing adverse T-cell activation. Anti-pT181 antibodies are reactive to pTau in human AD brains, engage pT181+ tau in human brain lysates, and are central nervous system bioavailable. DISCUSSION Our results suggest the translational utility of pT181-QB against tauopathies.
Highlights • Icosahedral display of phosphorylated tau at threonine 181 (pT181) Qß virus-like particle surface ("pT181-Qß" vaccine) induces a robust immune response in mice and in non-human primates (NHPs) • pT181-Qß vaccination reduces pathological tau (pTau) and brain atrophy, and improves memory and motor function in PS19 and hTau mice. • pT181-Qß vaccination-induced immunoglobulin Gs (IgGs) are safe, Th2 skewed (anti-inflammatory), specific to pTau in human AD brain, and efficiently engage pT181 in NHPs and human brain lysate. • pT181+ tau in human plasma correlates with the neurofilament light in subjects with mild cognitive impairment (MCI)-suggesting the presence of pT181-Qß vaccine target in the early disease state.
RESEARCH IN CONTEXT Systematic review: A literature review of PubMed and other literature sources suggests that the pathological modifications in tau protein strongly correlate with the cognitive decline in Alzheimer's disease (AD) and related dementias. As such, many pre-clinical and clinical trials have been targeting pathological tau to determine if such an approach benefits patients. Emerging clinical trials using monoclonal antibodies (mAbs) against different regions of tau show positive results in secondary outcomes of cognitive stabilization. Even if the mAb is approved for tau, repeated infusions of mAbs may have compliance issues in elderly patients and short-lived antibody responses upon active immunizations. The relevant citations and clinical trials are included where appropriate. Interpretation: Our study suggests that display of phosphorylated tau (on T181) peptide on the virus-like particles (VLPs) from Qß bacteriophage induced a robust immune response, reduced tau pathology, prevented brain atrophy, and improved memory, and that the immunoglobulin Gs (IgGs) from immunized sera engaged the target in vaccinated non-human primates (rhesus macaques) and human AD brains. Future directions: Targeting pT181-positive tau with pT181-Qß vaccination may in Phase 0/1 clinical trials validate the safety, immunogenicity, and therapeutic efficacy of pT181-Qß vaccination in patients with AD and related tauopathies.
The study has been published in Alzheimer’s & Dementia. YES, it is PEER-REVIEWED.
• alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
• hscnews.unm.edu/news/unm-res...
This woman has me saying “I’ll see you in court, sir” at least 3 times a day now
We live in the dumbest timeline ever.
You think you're built for revolution and then your Uber driver yells at you for slamming the door and you know it's gonna ruin your weekend
Jan 2025: “THIS IS THE TRUMP STOCK MARKET BECAUSE MY POLLS AGAINST BIDEN ARE SO GOOD THAT INVESTORS ARE PROJECTING THAT I WILL WIN, AND THAT WILL DRIVE THE MARKET UP.”
April 2025: “This is Biden’s Stock Market, not Trump’s."
Everything seems overwhelming...that's an understatement. So, here's a pep talk for all of you (and me) this morning:
Just Win The Day. 💪
Anyone else starting to see the local fb meltdowns over huge import charges being added to temu/shein orders this morning?
Just for those who may be a little confused: Hakeem Jeffries and Cory Booker’s sit-in on the Capitol steps to protest Trump’s brutal agenda isn’t performative. Wearing an overnight maxi pad on your ear after an “assassination attempt” is performative.
I feel like I’m losing my mind with the lack of wall to wall coverage on disappearing *children with cancer*
i keep saying this, but it’s not 5% of the uproar that came from Biden’s debate.
“kids peeing in litter boxes”, a thing that never happened, got orders of magnitude more coverage.
